Engineered t cells take on lymphoma in early trial

NCT ID NCT02917083

Recruiting now Disease control Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard therapy. The treatment uses the patient's own T cells, which are genetically modified to recognize and attack cancer cells carrying the CD30 protein. Up to 60 participants will receive one infusion of these CD30 CAR T cells after chemotherapy to make room for the cells to grow. The main goal is to check safety and find the best dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD30 CAR T cells (genetically modified immune cells)
What this could lead to: If this works, it could point toward a new treatment option for people with lymphoma that has come back after other treatments.
What could go wrong: This is a very early Phase 1 trial with only 60 people, focused on safety. The cells may not last long in the body, and it is unknown if they will effectively fight the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CD30-POSITIVE LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anaplastic large cell lymphoma Hodgkins lymphoma lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN'S LYMPHOMA NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Houston Methodist Hospital
RECRUITING

Houston, Texas, 77030, United States
Texas Children's Hospital
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.